34766 Federal Register / Vol. 74, No. 136 / Friday, July 17, 2009 / Notices 

Program Operations, Scientific Review 

Branch, P.O. Box 12233, Research Triangle 

Park, NC 27709. (919) 541–1446. 

eckertt1@niehs.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.115, Biometry and Risk 

Estimation—Health Risks from 

Environmental Exposures; 93.142, NIEHS 

Hazardous Waste Worker Health and Safety 

Training; 93.143, NIEHS Superfund 

Hazardous Substances—Basic Research and 

Education; 93.894, Resources and Manpower 

Development in the Environmental Health 

Sciences; 93.113, Biological Response to 

Environmental Health Hazards; 93.114, 

Applied Toxicological Research and Testing; 

93.701, ARRA Related Biomedical Research 

and Research Support Awards, National 

Institutes of Health, HHS) 

Dated: July 10, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–17044 Filed 7–16–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Aging; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Aging Special Emphasis Panel. ARRA–RC2– 

SEP–9. 

Date: July 23, 2009. 

Time: 1 p.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute on Aging, 

Gateway Building, 7201 Wisconsin Avenue, 

Suite 2C212, Bethesda, MD 20814. 

(Telephone Conference Call) 

Contact Person: Alicja L Markowska, PhD, 

DSC, Scientific Review Officer, Scientific 

Review Branch, National Institute on Aging, 

7201 Wisconsin Avenue, Suite 2C212, 

Bethesda, MD 20892, 301–496–9666, 

markowsa@nia.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: National Institute on 

Aging Special Emphasis Panel. ARRA–RC2– 

SEP–10. 

Date: August 5, 2009. 

Time: 10 a.m. to 2 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute on Aging, 

Gateway Building, 7201 Wisconsin Avenue, 

Suite 2C212, Bethesda, MD 20814. 

(Telephone Conference Call). 

Contact Person: Alicja L Markowska, PhD, 

DSC, Scientific Review Officer, Scientific 

Review Branch, National Institute on Aging, 

7201 Wisconsin Avenue, Suite 2C212, 

Bethesda, MD 20892, 301–496–9666, 

markowsa@nia.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.866, Aging Research; 

93.701, ARRA Related Biomedical Research 

and Research Support Awards, National 

Institutes of Health, HHS) 

Dated: July 9, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–17041 Filed 7–16–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Environmental 

Health Sciences; Amended Notice of 

Meeting 

Notice is hereby given of a change in 

the meeting of the National Institute of 

Environmental Health Sciences Special 

Emphasis Panel, July 30, 2009, 2 p.m. to 

July 30, 2009, 4:30 p.m., NIEHS/ 

National Institutes of Health, Keystone 

Building, 530 Davis Drive, Research 

Triangle Park, NC 27709 which was 

published in the Federal Register on 

July 2, 2009, FR E9–15689. 

The meeting date was changed from 

July 30, 2009 to August 12, 2009 and the 

meeting time was changed from 2 p.m. 

to 2:30 p.m. The meeting is closed to the 

public. 

Dated: July 9, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–17039 Filed 7–16–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of Exclusive 

License: Use of CD47 Antibodies, 

Antisense Oligonucleotides, and Small 

Molecules To Treat Disease Affecting 

the Vascular System 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: This is notice, in accordance 

with 35 U.S.C. 209(c)(1) and 37 CFR 

part 404.7(a)(1)(i), that the National 

Institutes of Health, Department of 

Health and Human Services, is 

contemplating the grant of an exclusive 

patent license to practice the inventions 

embodied in U.S. Provisional Patent 

Application No. 60/850,132, filed 

October 6, 2006, now abandoned (HHS 

Ref. No. E–227–2006/0–US–01); U.S. 

Provisional Patent Application No. 60/ 

864,153, filed November 02, 2006, now 

abandoned (HHS Ref. No. E–227–2006/ 

1–US–01); U.S. Provisional Patent 

Application No. 60/888,754, filed 

February 07, 2007, now abandoned 

(HHS Ref. No. E–227–2006/2–US–01); 

U.S. Provisional Patent Application No. 

60/910,549, filed April 06, 2007, now 

abandoned (HHS Ref. No. E–227–2006/ 

3–US–01); U.S. Provisional Patent 

Application No. 60/956,375, filed 

August 16, 2007, now abandoned (HHS 

Ref. No. E–227–2006/4–US–01); PCT 

Patent Application No. PCT/2007/ 

080647, filed October 5, 2007, now 

abandoned (HHS Ref. No. E–227–2006/ 

5–PCT–01); U.S. Patent Application No. 

12/444,364, filed October 5, 2007 (HHS 

Ref. No. E–227–2006/5–US–02); 

Canadian Patent Application (not yet 

determined) (HHS Ref. No. E–227–2006/ 

5–CA–03); Australian Patent 

Application No. 2007319576, filed 

October 5, 2007 (HHS Ref. No. E–227– 

2006/5–AU–04); and European Patent 

Application No. 07868382.8, filed 

October 5, 2007 (HHS Ref. No. E–227– 

2006/5–EP–05), all of which are entitled 

‘‘Prevention of Tissue Ischemia, Related 

Methods and Compositions’’, developed 

by Dr. David Roberts (NCI), Dr. Jeffrey 

Isenberg, and Dr. William Frazier. The 

patent rights in these inventions have 

been assigned to the United States of 

America. The prospective exclusive 

license territory may be ‘‘worldwide’’, 

and the field of use may be limited to: 

(1) ‘‘The use of antibodies including 

humanized antibodies reacting with 

CD47 or related antigens, precursors, or 

molecules, and isolated and/or 

recombinant fragments, and conjugates 

mstockstill on DSKH9S0YB1PROD with NOTICES

Federal Register / Vol. 74, No. 136 / Friday, July 17, 2009 / Notices 34767 

with an affinity for CD47 for the 

preservation or resuscitation of organs 

and tissues for transplantation’’; (2) ‘‘the 

use of antibodies including humanized 

antibodies reacting with CD47 or related 

antigens, precursors, or molecules, and 

isolated and/or recombinant fragments, 

and conjugates with an affinity for CD47 

for treating or preventing vascular 

diseases, including but not limited to, 

pulmonary hypertension, sickle cell 

disease, myocardial infarction, stroke, 

and tissue ischemia resulting from 

trauma and surgical procedures’’; (3) 

‘‘the use of antisense oligonucleotides or 

RNA formulations of stabilized 

composition to reduce expression of 

CD47 for treating wounds and/or burns 

and for use in reconstructive surgery’’; 

and (4) ‘‘use of small molecules 

antagonists of CD47 for treating or 

preventing vascular diseases including, 

but not limited to, thrombosis, 

hypertension, peripheral artery disease, 

renal artery disease, and ischemia 

resulting from atherosclerosis’’ to 

Vasculox, Inc., having an office in at 

least St. Louis, Missouri, U.S.A. The 

patent rights in these inventions have 

been assigned to the United States of 

America. 

DATES: Only written comments and/or 

applications for a license which are 

received by the NIH Office of 

Technology Transfer on or before 

September 15, 2009 will be considered. 

ADDRESSES: Requests for copies of the 

patent application, inquiries, comments, 

and other materials relating to the 

contemplated exclusive license should 

be directed to: Charlene A. Sydnor, 

Ph.D., Licensing and Patenting Manager, 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, MD 

20852–3804; Telephone: (301) 435– 

4689; Facsimile: (301) 402–0220; E-mail: 

sydnorc@mail.nih.gov. 

SUPPLEMENTARY INFORMATION: Nitric 

Oxide (NO) plays an important role as 

a major intrinsic vasodilator, and 

increases blood flow to tissues and 

organs. Disruption of this process leads 

to peripheral vascular disease, ischemic 

heart disease, stroke, diabetes and many 

more significant diseases. The inventors 

have discovered that the matrix protein 

thrombospondin1 (TSP1) blocks the 

beneficial effects of NO, and prevents it 

from dilating blood vessels and 

increasing blood flow to organs and 

tissues. Additionally, they discovered 

that this regulation requires TSP1 

interaction with its cell receptor, CD47. 

Relief of this inhibition in genetically 

altered mice lacking either TSP1 or 

CD47 results in dramatically improved 

blood flow and increased tissue 

oxygenation. Further, by using reagents 

such as monoclonal antibodies and 

peptides that block TSP1–CD47 

interaction, or agents such as antisense 

oligonucleotides or morpholinos that 

reduce the level of CD47 or TSP1, blood 

flow can dramatically increase to 

ischemic tissues in vivo. Inhibition of 

TSP1 signaling at the level of CD47 

expression and/or activation 

significantly improves the survival of 

tissue in an ischemic environment. 

The prospective exclusive license will 

be royalty bearing and will comply with 

the terms and conditions of 35 U.S.C. 

209 and 37 CFR part 404.7. The 

prospective exclusive license may be 

granted unless within sixty (60) days 

from the date of this published notice, 

the NIH receives written evidence and 

argument that establishes that the grant 

of the license would not be consistent 

with the requirements of 35 U.S.C. 209 

and 37 CFR part 404.7. 

Applications for a license in the field 

of use filed in response to this notice 

will be treated as objections to the grant 

of the contemplated exclusive license. 

Comments and objections submitted to 

this notice will not be made available 

for public inspection and, to the extent 

permitted by law, will not be released 

under the Freedom of Information Act, 

5 U.S.C. 552. 

Dated: July 10, 2009. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E9–17038 Filed 7–16–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Health Resources and Services 

Administration 

Section 330A(e) of the Public Health 

Service Act, as Amended (42 U.S.C. 

254c(e)) and Section 317(k)(2) of the 

Public Health Service Act, as Amended 

(42 U.S.C. 247b(k)(2)) 

AGENCY: Health Resources and Services 

Administration, HHS. 

ACTION: Notice of Single Source Grant 

Award to Lincoln County Health 

Department in Libby, MT. 

SUMMARY: The Health Resources and 

Services Administration (HRSA) is 

issuing a new single source award 

through the Rural Health Care Services 

Outreach Grant Program and the Centers 

for Disease Control and Prevention’s 

(CDC) screening grant program authority 

to Lincoln County Health Department 

(LCHD) in Libby, Montana. A serious 

public health problem has been 

identified in Lincoln County, Montana, 

as residents in this rural community 

have been adversely affected by the 

asbestos released from a vermiculite 

mine. The asbestos-related diseases in 

which Lincoln County residents have 

been diagnosed include asbestosis, lung 

cancer, mesothelioma, and others. The 

purpose of this demonstration grant 

would be to provide care management 

for Lincoln County residents with 

asbestos-related diseases. The grant will 

provide funds to support the 

coordination and payment of care for 

asbestos-related diseases among such 

entities as hospitals, clinics, specialty 

care providers, and others involved in 

the care and treatment of this service 

population. 

SUPPLEMENTARY INFORMATION: 

Intended Recipient of the Award: 

Lincoln County Health Department in 

Libby, Montana. 

Amount of the Award FY 2009: It is 

anticipated that up to $6,000,000 will be 

available from all sources for a 2-year 

project period from August 1, 2009— 

July 31, 2011. Of the $6,000,000, 

$2,000,000 will be available from CDC 

to support this effort. The remaining 

$4,000,000 will be awarded by HRSA’s 

Office of Rural Health Policy’s Rural 

Health Care Services Outreach Program, 

of which $2,000,000 will be provided 

the first year and an additional 

$2,000,000 will be provided the second 

year. Funding beyond the first year, 

however, is dependent on the 

availability of appropriated funds, 

grantee satisfactory performance, and a 

decision that continued funding is in 

the best interest of the Federal 

Government. 

Project Period: The project period for 

this grant is August 1, 2009, through 

July 31, 2011. 

Authority: This activity is funded 

under the authority of HRSA’s Rural 

Health Care Services Outreach Program, 

statutory authority Section 330A(e) of 

the Public Health Service Act, as 

amended (42 U.S.C. 254c(e)); and the 

CDC’s statutory authority Section 

317(k)(2) of the Public Health Service 

Act, as amended (42 U.S.C. 247b(k)(2)). 

The authority for the single source 

award is HHS Grants Policy Directive 

2.04, Awarding Grants. 

Catalogue of Federal Domestic 

Assistance Number: HRSA’s Rural 

Health Care Services Outreach Grant: 

93.912. CDC Screening Program: 93.161. 

Justification for Single Source 

Awards: Because of the serious public 

health problem in Lincoln County, 

Montana, and the prevalence of 

mstockstill on DSKH9S0YB1PROD with NOTICES